ATE519857T1 - Lichtemittierende mikroorganismen und viren für die diagnose von erkrankungen die mit verletztem oder entzündetem gewebe zusammenhängen - Google Patents

Lichtemittierende mikroorganismen und viren für die diagnose von erkrankungen die mit verletztem oder entzündetem gewebe zusammenhängen

Info

Publication number
ATE519857T1
ATE519857T1 AT03735553T AT03735553T ATE519857T1 AT E519857 T1 ATE519857 T1 AT E519857T1 AT 03735553 T AT03735553 T AT 03735553T AT 03735553 T AT03735553 T AT 03735553T AT E519857 T1 ATE519857 T1 AT E519857T1
Authority
AT
Austria
Prior art keywords
inflamed tissue
injured
viruses
protein
light
Prior art date
Application number
AT03735553T
Other languages
English (en)
Inventor
Alader Szalay
Shahrokh Shabahang
Yong Yu
Original Assignee
Genelux Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelux Corp filed Critical Genelux Corp
Application granted granted Critical
Publication of ATE519857T1 publication Critical patent/ATE519857T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1896—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0097—Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
AT03735553T 2002-06-05 2003-06-05 Lichtemittierende mikroorganismen und viren für die diagnose von erkrankungen die mit verletztem oder entzündetem gewebe zusammenhängen ATE519857T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02012552A EP1369491A1 (de) 2002-06-05 2002-06-05 Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
PCT/EP2003/005907 WO2003104485A2 (en) 2002-06-05 2003-06-05 Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue

Publications (1)

Publication Number Publication Date
ATE519857T1 true ATE519857T1 (de) 2011-08-15

Family

ID=29433119

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03735553T ATE519857T1 (de) 2002-06-05 2003-06-05 Lichtemittierende mikroorganismen und viren für die diagnose von erkrankungen die mit verletztem oder entzündetem gewebe zusammenhängen

Country Status (11)

Country Link
US (1) US8137904B2 (de)
EP (2) EP1369491A1 (de)
JP (1) JP4390699B2 (de)
CN (1) CN1668758A (de)
AT (1) ATE519857T1 (de)
AU (2) AU2003236696A1 (de)
CA (1) CA2488227A1 (de)
IL (2) IL165350A0 (de)
RU (1) RU2375456C2 (de)
SG (1) SG165992A1 (de)
WO (1) WO2003104485A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1281767A3 (de) 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
EP1369491A1 (de) 2002-06-05 2003-12-10 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
RU2376371C2 (ru) * 2003-06-18 2009-12-20 Дженелюкс Корпорейшн Модифицированные рекомбинантные вакцинирующие вирусы и другие микроорганизмы и их применение
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
WO2008156655A2 (en) 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
EP2173368A1 (de) * 2007-07-18 2010-04-14 Genelux Corporation Verwendung eines chemotherapeutischen mittels zur herstellung eines medikaments zur behandlung oder linderung einer mit einer onkolytischen virentherapie verbundenen unerwünschten nebenwirkung
WO2009126189A1 (en) 2008-01-11 2009-10-15 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
US20120052003A9 (en) * 2008-05-16 2012-03-01 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
CA2836299A1 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
JP6037259B2 (ja) * 2011-04-28 2016-12-07 国立大学法人 千葉大学 一酸化窒素を探知するための形質転換用組換えベクター、およびこれを用いた一酸化窒素センサ細胞
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
RU2513686C2 (ru) * 2012-08-24 2014-04-20 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pG1-Rm7, ОБЕСПЕЧИВАЮЩАЯ СИНТЕЗ ГИБРИДНОГО БЕЛКА G1-Rm7, И ГИБРИДНЫЙ БЕЛОК, СВЯЗЫВАЮЩИЙ ФАКТОР НЕКРОЗА ОПУХОЛЕЙ И ОБЛАДАЮЩИЙ БИОЛЮМИНЕСЦЕНТНОЙ АКТИВНОСТЬЮ
HK1220488A1 (zh) 2013-03-15 2017-05-05 The Children's Hospital Of Philadelphia 含有填充者/填充物多核苷酸序列的载体及其使用方法
CN116004721A (zh) 2013-07-12 2023-04-25 费城儿童医院 Aav载体和用于抗aav（腺相关病毒）中和抗体的检测
US9642586B2 (en) * 2014-08-18 2017-05-09 Siemens Aktiengesellschaft Computer-aided analysis of medical images
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018049362A1 (en) * 2016-09-12 2018-03-15 Massachusetts Institute Of Technology Transcriptional sensor for bile acids in bacteroides thetaiotaomicron
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN107418996A (zh) * 2017-04-19 2017-12-01 中国食品药品检定研究院 一种检测血管支架材料体外内皮化的模型制备及应用
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31643A (en) * 1861-03-05 Bons l
US213741A (en) * 1879-04-01 Improvement in portable platforms for fire and other ladders
US69491A (en) * 1867-10-01 Newark
EP0037441B1 (de) 1980-03-10 1984-05-09 Seiji Arakawa Pharmazeutische Zusammensetzungen zur zellulären Immunopotentialisation und als Antitumor-Mittel, Verfahren zu ihrer Herstellung und der darin verwendete Mikroorganismus
US4442203A (en) 1981-06-30 1984-04-10 Massachusetts Institute Of Technology Gene amplification assay for detecting tumor promoters
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4778759A (en) * 1982-07-09 1988-10-18 Boyce, Thompson Institute For Plant Research, Inc. Genetic engineering in cyanobacteria
US5221623A (en) * 1986-07-22 1993-06-22 Boyce Thompson Institute For Plant Research, Inc. Use of bacterial luciferase structural genes for cloning and monitoring gene expression in microorganisms and for tagging and identification of genetically engineered organisms
US6007806A (en) 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
US5283187A (en) * 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5650148A (en) * 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
DE69032841T2 (de) * 1989-01-23 1999-05-12 Chiron Corp., Emeryville, Calif. Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
US5618531A (en) * 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US5212082A (en) * 1991-03-13 1993-05-18 New York University Genetically modified tyrosine hydroxylase and uses thereof
HK1001832A1 (en) 1991-04-25 1998-07-10 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5800829A (en) * 1991-04-25 1998-09-01 Brown University Research Foundation Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core
US5718902A (en) * 1991-06-17 1998-02-17 The Regents Of The University Of California Double recombinant vaccinia virus vaccines
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
US5762959A (en) * 1992-05-29 1998-06-09 Vivorx, Inc. Microencapsulation of cells
JP4098355B2 (ja) * 1993-08-12 2008-06-11 ニューロテック ユーエスエー， インコーポレイテッド 遺伝的に改変された細胞を含む生体適合性免疫隔離カプセル
US6491905B1 (en) 1993-09-14 2002-12-10 The Uab Research Foundation Recombinant bacterial cells for delivery of PNP to tumor cells
FR2710536B1 (fr) 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
US6416754B1 (en) * 1994-03-03 2002-07-09 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
US5550050A (en) * 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US6093700A (en) * 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
US6455673B1 (en) * 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6649143B1 (en) 1994-07-01 2003-11-18 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
DE4425382C2 (de) 1994-07-19 1997-08-14 Univ Hohenheim Salmonella-Lebendimpfstoff
US5853717A (en) * 1994-07-20 1998-12-29 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5853385A (en) 1994-08-26 1998-12-29 Cytotherapeutics, Inc. Encapsulated PC12 cell transplants for treatment of Parkinson's disease
ES2154738T3 (es) * 1994-10-03 2001-04-16 Us Gov Health & Human Serv Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora.
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US5693533A (en) 1994-12-07 1997-12-02 The Goodwin Institue For Cancer Research Human breast carcinoma cell line capable of production of a spontaneously metastasizing tumor in animals for use in anticancer drug testing
US6150170A (en) 1998-05-03 2000-11-21 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US6503703B1 (en) * 1995-05-19 2003-01-07 Mount Sinai School Of Medicine Of New York University Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
US5704910A (en) * 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US5646298A (en) * 1995-06-07 1997-07-08 Procoron, Inc. Cyclopropylindole prodrugs
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US6025155A (en) * 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6077697A (en) * 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030033617A1 (en) * 1996-04-10 2003-02-13 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20020160970A1 (en) 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US5842431A (en) 1997-02-19 1998-12-01 Wu; Chong-Ming Rotating shuttle and presser plate arrangement
US6251384B1 (en) * 1997-04-28 2001-06-26 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
US6235968B1 (en) * 1997-04-28 2001-05-22 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
US6232523B1 (en) * 1997-04-28 2001-05-15 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
US6265557B1 (en) * 1997-05-09 2001-07-24 Loma Linda University Medical Center ABO histo-blood group O alleles of the baboon
US6713284B2 (en) * 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US6099848A (en) * 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
DE29924318U1 (de) * 1999-01-14 2002-09-19 Fleischmann, Wilhelm, Dr.med., 74321 Bietigheim-Bissingen Verbandsmaterial
US6087168A (en) 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
US6713293B1 (en) * 1999-02-08 2004-03-30 Friedrich Grummt Encapsulated cells containing an amplified expression vector as a drug delivery device
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6511967B1 (en) * 1999-04-23 2003-01-28 The General Hospital Corporation Use of an internalizing transferrin receptor to image transgene expression
CA2375189C (en) * 1999-05-28 2010-02-09 The Government Of The United States Of America A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
US6627190B2 (en) * 1999-07-12 2003-09-30 Saint Louis University Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
WO2001025399A2 (en) * 1999-10-04 2001-04-12 Vion Pharmaceuticals, Inc. Non-invasive tumor imaging by tumor-targeted bacteria
US6589531B1 (en) * 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
US20010029023A1 (en) * 2000-01-26 2001-10-11 Szalay Aladar A. Method for the evaluation of implantable materials
EP1294906B1 (de) 2000-03-17 2009-01-21 Anticancer, Inc. Optisches abbildungssystem zur darstellung der genexpression des gesamten körpers und anwendungen
DE10013511A1 (de) * 2000-03-20 2001-10-11 Brand Gmbh & Co Kg Mehrkanal-Pipettiereinrichtung sowie Pipettenschaft dafür
JP4231226B2 (ja) 2000-04-04 2009-02-25 新日本製鐵株式会社 圧延ｈ形鋼の製造方法
CA2341356C (en) * 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
CA2342040C (en) * 2000-09-21 2012-07-10 Kyowa Hakko Kogyo Co., Ltd. Anaerobic bacterium as a drug for cancer gene therapy
JP3642755B2 (ja) 2000-09-21 2005-04-27 純 天野 嫌気性菌を用いた遺伝子治療用医薬
JP2005520781A (ja) * 2001-07-09 2005-07-14 アンチキャンサー インコーポレーテッド 蛍光タンパク質をマーカーとして用いた感染の画像化
EP1281767A3 (de) 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
EP1281772A1 (de) * 2001-07-31 2003-02-05 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen zum Nachweis und zur Therapie von Krebs
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
WO2003030720A2 (en) * 2001-10-09 2003-04-17 The Children's Hospital Of Philadelphia Materials and methods for preventing or reducing scar formation
AU2002350235A1 (en) 2001-11-21 2003-06-10 The Johns Hopkins University Combination bacteriolytic therapy for the treatment of tumors
KR101142380B1 (ko) * 2001-12-31 2012-05-18 안티캔서, 인코포레이티드 박테리아 종양 치료의 모니터링 시스템
JP2005531507A (ja) * 2002-03-02 2005-10-20 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ストローマ細胞前駆体による抗癌物質の局所的な産生および／または送達方法
WO2003078640A2 (en) 2002-03-15 2003-09-25 Baxter International Inc. Recombinant drug-sensitive vaccinia virus as smallpox vaccine
US20030213007A1 (en) 2002-03-27 2003-11-13 Slattery Charles Wilbur Human milk produced by human mammary tissue implanted in non-human host animals and uses thereof
CA2486980A1 (en) 2002-05-29 2003-12-11 The Regents Of The University Of California Attenuated listeria spp. and methods for using the same
US20030228261A1 (en) 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
EP1369491A1 (de) 2002-06-05 2003-12-10 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
WO2004044175A2 (en) 2002-11-12 2004-05-27 Anticancer, Inc. Fluorescence guided cell capture
RU2376371C2 (ru) 2003-06-18 2009-12-20 Дженелюкс Корпорейшн Модифицированные рекомбинантные вакцинирующие вирусы и другие микроорганизмы и их применение
EP1489164A1 (de) 2003-06-18 2004-12-22 Genelux GmbH Rekombinante Vaccinia-Viren mit modifizierten F3-Genen, Verwendungen davon
EP1526185B1 (de) 2003-10-22 2012-09-12 Genelux Corporation Verwendung von Mikroorganismen oder Zellen zur Autoimmunisierung gegen Tumoren
DE60329594D1 (de) 2003-08-14 2009-11-19 Genelux Corp Methode zur Herstellung eines Polypeptides, einer RNA oder einer anderen Verbindung in Tumorgewebe
WO2005057488A2 (en) 2003-12-03 2005-06-23 Anticancer, Inc. Modular system for multi-color, whole body fluorescence imaging
US20080038204A1 (en) 2004-01-26 2008-02-14 Meng Yang Whole Body Imaging Using Portable Observation Systems
TW200819540A (en) * 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
WO2008100292A2 (en) * 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
EP2173368A1 (de) * 2007-07-18 2010-04-14 Genelux Corporation Verwendung eines chemotherapeutischen mittels zur herstellung eines medikaments zur behandlung oder linderung einer mit einer onkolytischen virentherapie verbundenen unerwünschten nebenwirkung
WO2009054996A2 (en) * 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
WO2009126189A1 (en) * 2008-01-11 2009-10-15 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
US20120052003A9 (en) 2008-05-16 2012-03-01 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy

Also Published As

Publication number Publication date
US8137904B2 (en) 2012-03-20
IL165350A (en) 2012-03-29
AU2008202946B2 (en) 2011-03-24
EP1509617A2 (de) 2005-03-02
EP1509617B1 (de) 2011-08-10
CN1668758A (zh) 2005-09-14
RU2004135547A (ru) 2006-11-20
CA2488227A1 (en) 2003-12-18
WO2003104485A2 (en) 2003-12-18
US20050249670A1 (en) 2005-11-10
EP1369491A1 (de) 2003-12-10
IL165350A0 (en) 2006-01-15
JP4390699B2 (ja) 2009-12-24
SG165992A1 (en) 2010-11-29
AU2008202946A1 (en) 2008-07-24
WO2003104485A3 (en) 2004-04-29
JP2005528922A (ja) 2005-09-29
AU2003236696A1 (en) 2003-12-22
RU2375456C2 (ru) 2009-12-10

Similar Documents

Publication Publication Date Title
ATE519857T1 (de) Lichtemittierende mikroorganismen und viren für die diagnose von erkrankungen die mit verletztem oder entzündetem gewebe zusammenhängen
DE60234793D1 (de) LIVP Stamm von Vaccinia-Virus zur Diagnose und Behandlung von Tumoren
Golub et al. Tetracyclines inhibit tissue collagenase activity: a new mechanism in the treatment of periodontal disease
KAUFMAN et al. Subdural empyema: analysis of 17 recent cases and review of the literature
BR0207310A (pt) Composição farmacêutica de interferon gama ou de pirfenidona com diagnósticos moleculares para o melhor tratamento de doenças pulmonares intersticiais
ATE85080T1 (de) Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
Reed et al. The first case of Ignatzschineria ureiclastica/larvae in the United States presenting as a myiatic wound infection
ATE395602T1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
ATE328899T1 (de) Zellkernlokalisierendes protein für beta-catenin
BARTON et al. Granuloma inguinale treated with streptomycin: Report of three cases
Nagaratnam et al. Anorexia nervosa in a 70 year old man
Martínez‐Doménech et al. Ultrasonography for early detection of non‐infectious necrotizing fasciitis secondary to cutaneous loxoscelism.
ATE278011T1 (de) Human dnase ii
Valerón-Almazán et al. Extensive, non-healing scalp ulcer associated with trauma-induced chronic osteomyelitis
DE50214523D1 (de) Nukleotidträger zur diagnose und therapie oraler erkrankungen
RU94008771A (ru) Способ прогнозирования продолжительности жизни онкологических больных 4-ой стадии заболевания после диагностических хирургических вмешательств
Bellastella et al. Comment on Mäkimattila et al. Every Fifth Individual With Type 1 Diabetes Suffers From an Additional Autoimmune Disease: A Finnish Nationwide Study. Diabetes Care 2020; 43: 1041–1047
Mamillapalli et al. Diverse roles of salivary microbiota in the onset and severity of periodontal disease
Harris Medical genetics
Tombleson et al. Immediate Tellurite Test in Diphtheria
ATE420210T1 (de) Diagnose des brustkrebsrisikos
Zambon et al. Tetracyclines inhibit tissue coiiagenase activity
Daly et al. Unilocular hydatid cyst disease in the mid-South
Singh et al. Multiple Eschars in Scrub Typhus
Chen et al. Ludwig's angina caused by a migrating fish bone

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties